Dr. David Halpert, M.D.
Nephrology (Kidney) (Nephrology Physician)
At a glance
- In the NPI registry since
- 2005
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Nephrology Physician primary
FL license ME70882 -
Specialist
FL license ME70882
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Payments from drug and device companies
In 2025, 1 companies reported 1 payments worth $49.52 in total to this clinician.
| Genentech, Inc. | $49.52 |
|---|
| Food and Beverage | $49.52 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 8 industry-funded studies in 2025, from 4 companies. The companies reported $714,338 in research payments for these studies, mostly to the institutions running them.
- A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age
ModernaTX, Inc. · Completed · NCT06602024 - A phase 2, parallel-group, double-blind study to investigate the safety and tolerability of LY3549492 compared with placebo in adult participants 55 to 80 years of age and bmi within 22 to 25 kg/M2
Eli Lilly and Company - An interventional phase 1B randomized doubleblind sponsoropen placebocontrolled study to investigate the safety tolerability and pharmacodynamic effect of PF07258669 compared to placebo in older participants includin…
Pfizer Inc. - A phase 3B study to investigate the efficacy and safety of retatrutide once weekly in participants without type 2 diabetes who have obesity or overweight: a randomized, double-blind, placebo-controlled trial (TRIUMPH-8)
Eli Lilly and Company - A phase 3,global,randomized,modified double blind,placebo controlled,study to evaluate the efficacy,immunogenicity,and safety of IVX A12,a respiratory syncytial virus RSV and human metapneumovirus hMPV virus like part…
AstraZeneca Pharmaceuticals LP - A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Effect of AZD0780 on Major Adverse Cardiovascular Events in Patients with Established Atherosclerotic Cardiovascular Diseas…
AstraZeneca Pharmaceuticals LP - A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk
Eli Lilly and Company · Completed · NCT05803421 - A phase 12 randomized study to evaluate the safety tolerability and immunogenicity of a modified rna COVID19 vaccine and a recombinant influenza vaccine administered as a single injection in healthy adults 50 years of…
Pfizer Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.